重组人白介素-11衍生物在血液恶性肿瘤治疗中的临床应用

目的探讨重组人白介素-11衍生物在血液恶性肿瘤治疗中的临床应用价值。方法血液恶性肿瘤患者50例，按随机数字表法分为观察组和对照组，各25例。两组患者在化疗结束后均给予常规预防出血、卧床等指导，当出现血小板〈50×10^9／L观察组开始应用重组人白介素-11进行治疗，对照组不予任何提升血小板的药物。两组患者在治疗过程中持续关注血液中血小板的含量变化，若发现体内器官有出血倾向或PLT〈10×10^9／L时，则予患者输注单采血小板，直至患者PLT基本恢复为止，分析两组患者的血小板输注情况、血小板下降的最低值、各个阶段的持续时间及不良反应的发生情况。结果对照组患者输注血小板15例，观察组8例，观察组患者在进行化疗后，血小板含量的最低值及血小板含量降低的持续时间均优于对照组，治疗过程两组患者未出现严重的不良反应，观察组出现肌肉酸痛1例，低热1例。结论重组人白介素-11衍生物用于血液恶性肿瘤的化疗中可提高血小板的最低值，缩短血小板降低的持续时间，且安全、可靠。

Objective To evaluate the clinical value of recombinant human interleukin-11 derivatives in the treatment of hematologic malignancies. Methods Fifty patients with malignant hematologic malignancies were divided into observation group and control group according to random number table method. Two groups of patients after the end of chemotherapy were given conventional bleeding, bed and other guidance, when the platelet〈50 × 10^9/L observation group began to use recombinant human interleukin-11 for treatment, the control group did not increase the platelet drugs. Two groups of patients in the course of treatment continued to pay attention to the changes in blood levels of platelets, if found in vivo organ bleeding tendency or PLT〈10 ×10^9/L, the patient was given a single platelet transfusion until the patient PLT basically recovered. Two groups of patients with platelet transfusion, the lowest platelet decline, the duration of each stage and the occurrence of adverse reactions were analyzed. Results In the control group, 15 patients with platelet transfusion and 8 patients in the observation group were treated with chemotherapy. The lowest level of platelet content and the duration of platelet reduction were better than those in the control group. There was no serious difference between the two groups in the treatment group. Adverse reactions of the observation group showed muscle soreness in 1 case, 1 case of low fever. Conclusion Recombinant human interleukin-11 derivatives can improve the minimum value of platelets and shorten the duration of thrombocytopenia in the chemotherapy of hematologic malignancies, and is safe and reliable.